Drug intelligence / Profile preview

Colosafe-L

Development stage: Unknown
Lead developer: Jointcare Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

**Colosafe-L** is an oral sustained-release fixed-dose gastrointestinal combination marketed by Jointcare Pharmaceuticals. Each capsule contains **levosulpiride 75 mg** and **rabeprazole 20 mg**. Rabeprazole suppresses gastric acid secretion through irreversible inhibition of the gastric hydrogen-potassium ATPase proton pump, while levosulpiride is a dopamine D2-receptor antagonist with prokinetic activity that promotes upper gastrointestinal motility and helps reduce reflux. The product is marketed for gastroesophageal reflux disease, intestinal ulcers, and irritable bowel syndrome.

Brand names: Colosafe-L
Other names: COLOSAFE LCOLOSAFE-LColosafe-L Capsule SR

Targets

DRD2 (Dopamine D2 Receptor)ATP4A (Potassium–transporting ATPase alpha chain 1)

Beyond the preview

Go deeper on Colosafe-L.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Colosafe-L.

Explore the full profile